Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLCHI-CORT trial in early-onset triple-vessel coronary heart disease
ChiCTR2600133118Phase 4Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colchicine and prednisone in coronary arteriosclerosis (4 arms), sponsored by Dongguan People's Hospital. Primary endpoint: Late lumen loss within the target lesion segment. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
colchicineprednisone
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2600133118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133118.